The Smartpatch is a sonophoresis-based, truly non invasive & wearable transdermal drug delivery platform for painless and environmentally friendly chronic subcut. injections without Needles/Cannulas
Current Status
- Working prototype validated on in vivo pig trials
- Granted patent on our innovative ultrasound generator
- Secured strategic partners for clinical trials, manufacturing and distribution
- Over 50 awards to medtech and social innovation from organizations such as MIT, Forbes, or Sanofi. Moreover, we have received the financial support of relevant players such as Merck, the Basque public healthcare system or BUPA Spain.
Problem or Opportunity
Most patients with chronic pathologies such as diabetes, multiple sclerosis, or autoimmunity require multiple daily injections or a 24/7 connection to a pump cannula that frequently gets obstructed and generates allergic reactions. 80% of chronic patients identify needles/cannulas as the main reason to fail on treatment goals, which generates 20% more costs to healthcare systems, and leads to complications and early death. The 16B needles used every year for drug delivery are biohazardous waste, which causes 2,700 daily accidental injuries in the EU, costing €3 Bn/y.
Solution (product or service)
Our wearable SMARTPATCH is the first truly non-invasive delivery patch for large molecules, completely free of needles & cannulas. It ́s based on a patented ultrasonic system that transforms electric currents into sound vibrations to open skin pores temporarily and deliver macromolecular drugs through them. These ultrasound (US) waves enlarge the skin pores without pain or damage and force drugs like insulin, heparin, or EPO (>50KDa) to reach the hypodermis and capillary vessels (Sonophoresis).
Business model
Licensing agreements with Pharma companies for an exclusive link between the SMARTPATCH and their molecule in particular geographies (device+drug) + purchase orders of pre-defined amounts: - Upfront payment to cover operational costs of adapting the supply chain and the device. - Main device: pre-agreed units and 3-year warranty. We expect reaching reimbursement in 2027 after positive pharmacoeconomic studies. Needles produce $3B/y in accidental injuries. If only 1% of them are avoided, the Smartpatch could save $30M/y, added to the costs saved by improving treatment adherence and results.
